Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Go back to Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1102.08 +3.51 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1098.57 | 52 Week High | $88.16 | |||
| Open | $1112.24 | 52 Week Low | $67.88 | |||
| Day High | $1119.45 | P/E | 255.11 | |||
| Day Low | $1093.15 | EPS | $4.32 | |||
| Volume | 3,014,521 | |||||
